Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cmet.2019.07.005 | DOI Listing |
Publication Analysis
Top Keywords
drug metabolism
4
metabolism community
4
community effort
4
effort levodopa
4
levodopa l-dopa
4
l-dopa primary
4
primary treatment
4
treatment parkinson's
4
parkinson's disease
4
disease gut
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!